Drugs / TCK-276
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05437419 | Aug 2022 → Jul 2023 | rheumatoid arthritis | Teijin America, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-10-23 | Teijin Pharma Limited | 関節リウマチ治療薬候補「TCK-276」に関する独占的ライセンス契約を英国バイオテック企業と締結 teijin-pharma.co.jp ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCK-276 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05437419 ↗ |
| Action | Inhibit | “TCK-276, a novel CDK4/6 inhibitor” PMID 39002122 ↗ Mar 2025 |
| Target | CDK4 | “TCK-276, a novel CDK4/6 inhibitor” PMID 39002122 ↗ Mar 2025 |